LeMaitre Vascular, Inc.

Welcome to the LaMete Vascular Q2 2025 Fiscal Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LaMete Vascular. Please go ahead, sir.

Thank you, Operator. Good afternoon, and thank you for joining us. on our Q2 2025 conference call. With me on today's call is our CEO, George LeMaitre, and our President, Dave Roberts. Before we begin, I'll read our safe harbor statement. Today we'll be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, August 5th, 2025, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosures of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures, such as organic sales growth. A reconciliation of GAAP to non-GAAP measures discussed in the call is contained in the associated press release and is available in the investor relations section of our website, www.lemate.com. I'll now turn the call over to George Lemaitre.

Thanks, Dorian. Q2 was strong across the board, with sales up 15%, a 70% gross margin, and EPS up 16%. As a result, we're increasing full-year guidance for sales, gross margin, up income, and EPS. Q2 sales were led by catheters, up 27%, and graphs, up 19%, while valvetones and chunks were both up 13%. By geography, EMEA grew 23%, Americas 12%, and APAC 12%. Our international autograph launch exceeded expectations in Q2, with sales of 420,000, up from 185,000 in Q1. International autograph sales should surpass 2 million in full year 2025. Autograph is currently approved in the US, EU, UK, Australia, New Zealand, South Africa, Israel, Thailand, and Malaysia. And 2026 approvals are likely in Canada, Korea, and Singapore. Allograft was the company's largest U.S. product in 2024 with $37 million in U.S. sales. As for RestoreFlow, we continue to anticipate at least one European approval in 2025, either Ireland or Germany. Unfortunately, there is no EU-wide approval for Allografts, but one approval in Europe should expedite others. To support the impending European launches, we are opening a RestoreFlow distribution facility in Dublin this year. RestoreFlow is currently approved in just three countries, the U.S., the U.K., and Canada. In China, our Xenosure vascular patch remains on track for final submission in Q4. Approval might come in 2026. This follows the Q4 2024 Chinese Xenosure cardiac patch approval. We ended Q2 with 164 sales reps and 33 sales managers, and our international Go Direct efforts continue. We recently posted our first Portuguese and Czech direct-to-hospital sales. 2025 is shaping up to be another year of healthy sales and profit growth. I'll now turn the call over to Dorian.